Scholarlink

Purpose <p>Rare cases of colorectal cancer patients with exceptionally good or poor prognosis often remain overlooked, limiting insights into prognostic factors and underlying mechanisms.</p> Methods <p>This study developed an&#xa0;analytical framework to investigate cancer patients at the extremes using tumor mutational burden (TMB). By analyzing data from 1277 colorectal cancer patients who did not receive immunotherapy, this analysis assessed how patient survival varies with a broad range of TMB levels.</p> Results <p>Among patients with TMB ≤ 10 mutations per megabase (mut/Mb), increasing TMB was associated with worse survival outcomes. In contrast, patients with TMB &gt; 10 mut/Mb showed &#xa0;increasingly&#xa0;improved survival. Notably, a small subgroup (3.83%) with TMB &gt; 60 mut/Mb had significantly better survival outcomes.</p> Conclusions <p>These findings highlight TMB’s dual role in colorectal cancer progression. This study suggests that atypical patients can coexist within the same “disease continuum” with typical patients, under the universal context unified by a shared cancer hallmark. TMB provides a useful biomarker for identifying these extremes, offering a clinical metric to better predict patient outcomes and personalize treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes

  • 期刊论文

  • 发表日期：

    2025年2月21日

查看全文
  • Ming Zheng

摘要

Purpose

Rare cases of colorectal cancer patients with exceptionally good or poor prognosis often remain overlooked, limiting insights into prognostic factors and underlying mechanisms.

Methods

This study developed an analytical framework to investigate cancer patients at the extremes using tumor mutational burden (TMB). By analyzing data from 1277 colorectal cancer patients who did not receive immunotherapy, this analysis assessed how patient survival varies with a broad range of TMB levels.

Results

Among patients with TMB ≤ 10 mutations per megabase (mut/Mb), increasing TMB was associated with worse survival outcomes. In contrast, patients with TMB > 10 mut/Mb showed  increasingly improved survival. Notably, a small subgroup (3.83%) with TMB > 60 mut/Mb had significantly better survival outcomes.

Conclusions

These findings highlight TMB’s dual role in colorectal cancer progression. This study suggests that atypical patients can coexist within the same “disease continuum” with typical patients, under the universal context unified by a shared cancer hallmark. TMB provides a useful biomarker for identifying these extremes, offering a clinical metric to better predict patient outcomes and personalize treatment strategies.